Federal judge upholds Cabometyx patent in Exelixis' generic battle
A federal judge upheld a key patent on Exelixis’ cancer drug Cabometyx on Thursday, dealing a blow to MSN Laboratories’ potential generic version.
Exelixis filed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.